Pure Global AI
NCT06390241Not yet recruiting

Avidination for RadionuclideTHerapy in Nonpalpable Breast Cancer

Avidination for Radionuclide THerapy (A.R.THE.) in Nonpalpable Breast Cancer
Istituto Scientifico Romagnolo per lo Studio e la cura dei TumoriPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Breast Cancer
Drug/Device/Intervention
Avidin-biotin-Dota-90Y
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Timeline & enrollment
Phase
Phase 1
Start date
Jun 01, 2024
End date
Jan 01, 2025
Enrollment
52 participants
Primary outcome

Safety of avidin-biotin-Dota-90Y,Safety of avidin-biotin-Dota-90Y,Anti-tumor activity of avidin-biotin-Dota-90Y

Summary

This is an interventional, open-label, non comparative phase 2 trial enrolling patients with
 nonpalpable breast cancer

ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastCarcinoma in situ of breast, unspecifiedMalignant neoplasm: Breast, unspecifiedOther carcinoma in situ of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06390241
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06390241 through Pure Global AI's free database. This Phase 1 trial is sponsored by Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori and is currently Not yet recruiting. The study focuses on Breast Cancer. Target enrollment is 52 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.